By: Benzinga
Osiris Legal Team Responds, Says Reviewing All of Legal-Regulatory Options, Calls TheStreet Story 'Misleading'
Earlier today, Osiris Therapeutics, Inc. (NASDAQ: OSIR ), announced that it has reached agreement with the United States Food and Drug Administration (FDA) regarding the regulatory pathway for its Biosurgery products, Grafix^® and Ovation^®. In its press release regarding this agreement, Osiris addressed the recent concerns raised with respect to the regulatory status
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here